SCHEMBL5082860

SCHEMBL5082860

CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)nc1)C1CCN(C(=O)CC(C)(C)C)CC1

nearest known ligand 0.49

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 18/20 0.49
KCNH2 Q12809 1/20 0.39
CYP3A4 P08684 1/20 0.39
STAT3 P40763 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3979396 0.89 GPR119 (0.50) GPR119KCNH2STAT3
SCHEMBL3984054 0.88 GPR119 (0.48) GPR119KCNH2STAT3
SCHEMBL5079985 0.87 GPR119 (0.45) GPR119KCNH2
SCHEMBL14190997 0.87 GPR119 (0.47) GPR119KCNH2CYP3A4
SCHEMBL3982861 0.87 GPR119 (0.53) GPR119
SCHEMBL12569747 0.86 GPR119 (0.66) GPR119
SCHEMBL5082124 0.86 GPR119 (0.44) GPR119CYP3A4
SCHEMBL5082159 0.84 GPR119 (0.48) GPR119KCNH2
SCHEMBL3986279 0.84 GPR119 (0.51) GPR119KCNH2
SCHEMBL5079941 0.84 GPR119 (0.42) GPR119KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US claimed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
WO-2008025798-A1 PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS BIOVITRUM AB (PUBL) (SE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103123-A1 New compounds GPR119, GPR139, GPR180 GPR119 1/4885KCNH2 1859/4885CYP3A4 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.